Nieves Martinez Lago MD PhD· @DraMartinezLago · X·· 2 days agoScore70
Body · original
#ESMO26 🧬 TQB2102 | Phase II
👥 86 pts | 1L HER2+ GC/GEJ
💊 HER2 ADC + bemotrizumab ± capecitabine
🎯 ORR:
• Doublet: 69.6%
• Triplet: 84.2% (95.8% at 6 mg/kg)
📈 mPFS: 12.68 vs 11.04 mo
⏳ OS immature
🔎 Promising activity; randomized validation needed.
@OncoAlert
422 views · 5 likes · 6 reposts · 0 replies
Conference abstracts
2876ROmatched by Rapid oral 1: Gastrointestinal tumour, upper digestive
TQB2102, a novel HER2 bispecific antibody-drug conjugate, combined with bemotrizumab with or without capecitabine as first-line therapy for HER2-positive advanced gastric/gastroesophageal junction cancer: A phase II study
https://esmocongress.esmo.orgSource: Nieves Martinez Lago MD PhD · x.com